Frequently Asked Questions (FAQ)
Welcome to the FAQ section of Oncoscience GmbH. Here, we address common questions about our focus areas, including Nimotuzumab, clinical trials, and access to treatments for rare cancers. If your question isn’t listed here, feel free to contact us directly for more information.
About Nimotuzumab
Nimotuzumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a target molecule that is being investigated in various tumour types. The antibody is being investigated in clinical trials for indications such as glioma, head and neck cancer and nasopharyngeal carcinoma.
Nimotuzumab is currently not authorised in Europe. Under certain conditions, access via named patient programmes may be possible in individual countries. Availability is subject to the respective national regulations and is only granted on application by a doctor.
Nimotuzumab is being investigated in clinical trials for EGFR-positive tumours, including head and neck squamous cell carcinoma (HNSCC), glioma and nasopharyngeal carcinoma (NPC).
Nimotuzumab binds to the epidermal growth factor receptor (EGFR), a target molecule that is being researched in oncology. The targeted approach of EGFR antibodies is being investigated to understand potential differences in tolerability compared to conventional therapeutic approaches.
Access to Nimotuzumab
Under certain conditions, access to Nimotuzumab can be considered as part of a named patient programme. The application is made by the treating physician in accordance with the applicable national regulations. Further information on the framework conditions for possible access is available on request for healthcare professionals.
Under certain regulatory conditions, a named patient programme can provide access to treatments that are not yet approved in a particular country. This is possible in individual cases if the medical indication justifies this, and no authorised alternatives are available in accordance with the applicable regulations.
The possibility of reimbursement depends on the regulations of your country's healthcare system and the provisions of your insurance policy. For more information, please contact your healthcare provider or insurance company.
Clinical Trials
Yes, Nimotuzumab is being investigated worldwide in clinical trials for its potential efficacy and safety in EGFR-positive cancers.
Whether participation is possible depends on the inclusion criteria, including the type of cancer, health status and previous treatments. Information on ongoing trials can be obtained from your treating physician or official trial registries.
Clinical trials are important for testing new treatments, improving existing ones and gaining scientific insights into the safety and efficacy of therapies such as Nimotuzumab.
About Oncoscience GmbH
Oncoscience GmbH is a European pharmaceutical company active in the research and development of innovative approaches for rare cancers. Oncoscience GmbH holds the exclusive licence for nimotuzumab in Europe. The drug is currently in clinical development and is not authorised for commercial use in Europe.
Our focus is on research into rare and EGFR-positive cancers, including research into gliomas, head and neck cancers and nasopharyngeal carcinomas.
We support clinical research and collaboration with healthcare providers to investigate new research approaches and treatment options in oncology. Under certain conditions, regulatory programmes can provide access to innovative therapies such as Nimotuzumab.
General Information
Patients should consult their healthcare providers first. Physicians can contact us directly to request access to Nimotuzumab under the named patient program or for information about clinical trials.
Visit the Nimotuzumab page on our website for detailed information on the mechanism of action, ongoing clinical trials and regulatory access.